![Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade - eBioMedicine Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade - eBioMedicine](https://www.thelancet.com/cms/asset/932e4e98-2137-443e-a4b0-942fb7cc8597/gr1.jpg)
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade - eBioMedicine
![A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity | Nature Communications A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-18450-4/MediaObjects/41467_2020_18450_Fig1_HTML.png)
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity | Nature Communications
![Frontiers | Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort Frontiers | Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort](https://www.frontiersin.org/files/Articles/829665/fimmu-13-829665-HTML/image_m/fimmu-13-829665-g001.jpg)
Frontiers | Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort
![Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/53df1219-ef81-4be7-9e58-949baca55d1a/gr1_lrg.jpg)
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity
![Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom | Nature Microbiology Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom | Nature Microbiology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41564-021-00947-3/MediaObjects/41564_2021_947_Fig1_HTML.png)
Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom | Nature Microbiology
![Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling | National Institutes of Health (NIH) Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling | National Institutes of Health (NIH)](https://www.nih.gov/sites/default/files/news-events/news-releases/2020/20200810-preventio-covid.png)
Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling | National Institutes of Health (NIH)
![Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies | Molecular Pharmaceutics Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies | Molecular Pharmaceutics](https://pubs.acs.org/cms/10.1021/acs.molpharmaceut.2c00919/asset/images/medium/mp2c00919_0004.gif)
Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies | Molecular Pharmaceutics
![The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study - The Lancet Microbe The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study - The Lancet Microbe](https://www.thelancet.com/cms/attachment/8820d58a-2023-4025-a890-8e4e748d7dab/gr1_lrg.jpg)
The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study - The Lancet Microbe
![Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection - eClinicalMedicine Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection - eClinicalMedicine](https://www.thelancet.com/cms/attachment/17b20a5b-68af-4351-8bea-68fe7bfefdac/gr2_lrg.jpg)
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection - eClinicalMedicine
![Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 | NEJM Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2021/nejm_2021.384.issue-23/nejmc2103916/20220118/images/img_medium/nejmc2103916_f1.jpeg)
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 | NEJM
![IgA dominates the early neutralizing antibody response to SARS-CoV-2 | Science Translational Medicine IgA dominates the early neutralizing antibody response to SARS-CoV-2 | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.abd2223/asset/19ceee17-9a01-455e-a3f9-91447c3a50e6/assets/graphic/abd2223-f1.jpeg)